The company will report its financial results for the three and nine months ended September 30, 2017.
REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the three and nine months ended September 30, 2017, and will host a corporate update conference call and webcast at 8:30am Eastern Time on Wednesday, November 15, 2017.
| Conference Call & Webcast | ||
| Wednesday, November 15 @ 8:30am Eastern Time | ||
| Toll Free: | 888-811-5448 | |
| International: | 913-312-9330 | |
| Conference ID: | 5079955 | |
| Webcast: | http://public.viavid.com/index.php?id=126383 | |
| Replays, Available through November 29: | ||
| Toll-Free: | 844-512-2921 | |
| International: | 412-317-6671 | |
| Conference ID: | 5079955 | |
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
For more information, please visit www.foamixpharma.com.
| Contact: | US Investor Relations | |
| Ilan Hadar, CFO & Country Manager | Michael Rice | |
| Foamix Pharmaceuticals Ltd. | LifeSci Advisors, LLC | |
| +972-8-9316233 | 646-597-6979 | |
| ilan.hadar@foamixpharma.com | mrice@lifesciadvisors.com |
